Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04341623 · ClinicalTrials.gov registry record · NA
Xerosis and Use of Topical Moisturizer
A NA study of Xerosis Due to Atopic Dermatitis, sponsored by Wake Forest University Health Sciences.
- Active
- Registry status
- NA
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT04341623: Active NA study of Xerosis Due to Atopic Dermatitis, sponsored by Wake Forest University Health Sciences.
NCT04341623 is a NA study of Xerosis Due to Atopic Dermatitis that is active but no longer recruiting, run by Wake Forest University Health Sciences. The registered enrollment target is 35 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04341623, a NA study of Xerosis Due to Atopic Dermatitis, is active but no longer recruiting, sponsored by Wake Forest University Health Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary hypothesis is that routine measurement of trans epidermal water loss (TEWL) rates and stratum corneum (SC) hydration levels will promote patient adherence to maintenance moisturizer therapy and prevent disease relapse. The project will consist of a trial in which thirty subjects with xerosis receive moisturizer therapy and are randomized to receive either no intervention, a weekly electronic survey to assess patient's response to daily moisturizer, or daily monitoring of the effectiveness of a moisturizer with a portable hydration measurement device. The study team will measure adherence to daily moisturizer use objectively in all three groups with electronic monitors attached to the containers of the moisturizer. The adherence measure will allow the study determine how well moisturizers work for xerosis when that are well used. The study team anticipate that in the no intervention group, adherence will be abysmal and that in the group reporting their response to treatment weekly, adherence will be much better. This will give the study team negative and positive controls for assessing the effect of home barrier monitoring on treatment adherence.
Primary Outcome
Dry Skin/Ichthyosis Area and Severity Index (DASI)
Conditions Studied
Interventions
- OTHER Cetaphil Pro Eczema moisturizer
- BEHAVIORAL Electronic interaction
- BEHAVIORAL GPSkin
Study Locations (1)
North Carolina
- Wake Forest University Health Sciences Department of Dermatology - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2021-01-21 |
| Est. Completion | 2026-08 |
| Phase | NA |
What the registry record for NCT04341623 still lists
NCT04341623 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Xerosis Due to Atopic Dermatitis appearing as the primary indexed condition, and to 3 interventions - of which Cetaphil Pro Eczema moisturizer is the first listed.
NCT04341623 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT04341623 about?
NCT04341623 is a clinical study titled "Xerosis and Use of Topical Moisturizer". The primary hypothesis is that routine measurement of trans epidermal water loss (TEWL) rates and stratum corneum (SC) hydration levels will promote patient adherence to maintenance moisturizer therapy and prevent disease relapse. The project will consist of a trial in which thirty subjects with xer...
What is the current status of trial NCT04341623?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 35 participants. The study started on 2021-01-21. Estimated completion is 2026-08.
What conditions does trial NCT04341623 study?
This clinical trial studies the following conditions: Xerosis Due to Atopic Dermatitis.
What interventions are being tested in trial NCT04341623?
The interventions under investigation include: Cetaphil Pro Eczema moisturizer (OTHER), Electronic interaction (BEHAVIORAL), GPSkin (BEHAVIORAL).
Who is sponsoring clinical trial NCT04341623?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04341623 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04341623's enrollment target sits among peer trials
35 1564th of 2000 higher than 431 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI